Clinical significance of abdominal lymphadenopathy in chronic liver disease

Ultrasound Med Biol. 2002 Mar;28(3):297-301. doi: 10.1016/s0301-5629(01)00514-2.

Abstract

The possibility of assessing the relationship of ultrasound (US)-detected abdominal lymphadenopathy with etiology, biochemical findings, and histologic data in patients with chronic liver disease was evaluated. US examination of the upper abdomen was performed in 321 consecutive patients with various chronic liver disorders and 56 control patients. The prevalence of lymphadenopathy in chronic liver disease was 38%. This prevalence varied according to etiology of liver disease, from 50% in chronic hepatitis C virus (HCV) to less than 10% in alcoholic cirrhosis and hepatitis B-virus (HBV)-related chronic liver disease. Patients with lymphadenopathy showed significantly higher serum levels of AST and ALT, as well as greater histopathological severity on liver biopsy specimens. In anti-HCV positive patients, there were no differences in the prevalence of lymphadenopathy according to HCV genotypes, whereas lymphadenopathy occurred less frequently in responders to interferon therapy than in nonresponders.

MeSH terms

  • Abdomen / diagnostic imaging*
  • Analysis of Variance
  • Antineoplastic Agents / therapeutic use
  • Chronic Disease
  • Female
  • Humans
  • Interferon-alpha / therapeutic use
  • Liver / pathology*
  • Liver Diseases / diagnostic imaging*
  • Liver Diseases / pathology
  • Lymph Nodes / pathology
  • Lymphatic Diseases / diagnostic imaging*
  • Male
  • Middle Aged
  • Prospective Studies
  • Ultrasonography

Substances

  • Antineoplastic Agents
  • Interferon-alpha